Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA

Eur J Neurosci. 2008 Feb;27(3):580-92. doi: 10.1111/j.1460-9568.2008.06040.x.

Abstract

Tyrosine hydroxylase (TH)-immunoreactive (ir) neurones are detected in the striatum of animals after dopamine depletion and also in human parkinsonian patients. Although there is extensive evidence for TH-ir neurones in the lesioned rodent striatum, there are few details regarding the molecular phenotype of these neurones, regulation of their TH expression after l-3,4-dihydroxyphenylalanine (L-DOPA) treatment and their function. In the present study, we examined the time-course of appearance of TH-ir neurones in the mouse striatum after 6-hydroxydopamine (6-OHDA) lesion and determined their molecular phenotype. We found that TH-ir neurones appeared in the striatum as early as 3 days after a 6-OHDA lesion. By 1 week after the lesion, the number of TH-ir neurones started to decrease and this decrease progressed significantly over time. Treatment with L-DOPA increased both the number of TH-ir neurones and the intensity of their immunolabelling. The TH-ir neurones that appear after the 6-OHDA lesion in the striatum are not newly generated cells as they did not incorporate 5-bromo-2-deoxyuridine. We found that the vast majority of TH-ir neurones colocalized with dynorphin and enkephalin, suggesting that they are projection neurones of the direct and indirect striatal output pathways. TH-ir neurones did not express the dopamine transporter but half of them expressed amino acid decarboxylase, an enzyme required for dopamine synthesis. Finally, striatal TH-ir neurones are functionally active, expressing the neuronal activation marker FosB in response to L-DOPA treatment. Promotion of these striatal TH-ir neurones may be beneficial in Parkinson's disease, particularly in the early stages when dopamine denervation is incomplete.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers / analysis
  • Biomarkers / metabolism
  • Bromodeoxyuridine
  • Cell Count
  • Cell Proliferation / drug effects
  • Corpus Striatum / cytology
  • Corpus Striatum / metabolism*
  • Corpus Striatum / physiopathology
  • Denervation
  • Dopamine / biosynthesis
  • Dopamine / deficiency*
  • Dopamine Plasma Membrane Transport Proteins / metabolism
  • Immunohistochemistry
  • Levodopa / metabolism*
  • Levodopa / pharmacology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Nerve Degeneration / chemically induced
  • Nerve Degeneration / enzymology
  • Nerve Degeneration / physiopathology
  • Neural Pathways / metabolism
  • Neural Pathways / physiopathology
  • Neurons / cytology
  • Neurons / drug effects
  • Neurons / enzymology*
  • Opioid Peptides / metabolism
  • Oxidopamine
  • Parkinson Disease / metabolism
  • Parkinson Disease / physiopathology
  • Proto-Oncogene Proteins c-fos / metabolism
  • Substantia Nigra / metabolism*
  • Substantia Nigra / physiopathology
  • Sympatholytics
  • Tyrosine 3-Monooxygenase / metabolism*

Substances

  • Biomarkers
  • Dopamine Plasma Membrane Transport Proteins
  • Fosb protein, mouse
  • Opioid Peptides
  • Proto-Oncogene Proteins c-fos
  • Sympatholytics
  • Levodopa
  • Oxidopamine
  • Tyrosine 3-Monooxygenase
  • Bromodeoxyuridine
  • Dopamine